Harvard Bioscience Stock

Harvard Bioscience Stocks 2024

Harvard Bioscience Stocks

42.42 M

Ticker

HBIO

ISIN

US4169061052

WKN

578107

In 2024, Harvard Bioscience had 42.42 M outstanding stocks, a 0% change from the 42.42 M stocks in the previous year.

The Harvard Bioscience Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2026e42.42
2025e42.42
2024e42.42
202342.42
202241.4
202140.3
202038.6
201937.8
201836.5
201734.8
201634.2
201533.6
201433.2
201330.4
201229.8
201129.8
201029.4
200929.9
200831.4
200731.4
200631.1
200530.8
200431.1

Harvard Bioscience shares outstanding

The number of shares was Harvard Bioscience in 2023 — This indicates how many shares 42.42 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Harvard Bioscience earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Harvard Bioscience's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Harvard Bioscience’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Harvard Bioscience's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Harvard Bioscience Aktienanalyse

What does Harvard Bioscience do?

Harvard Bioscience Inc was founded in 1901 and is headquartered in Holliston, Massachusetts. The company is a global leader in providing instruments, technologies, and complete systems for science and research. Harvard Bioscience has established itself as one of the leading providers of products and solutions in the fields of life sciences and health research with over 100 years of industry experience. The business model of Harvard Bioscience is focused on delivering high-quality products and solutions for research needs. The company is divided into three business segments: Life Science Research Products, Preclinical Surgical Products, and Analytical Instruments. These business segments offer a variety of products, such as instruments for cell and molecular research, gene expression analysis devices, surgical instruments, and instruments for electrophysiology. The Life Science Research segment includes the business units Harvard Apparatus, Molecular Devices, and Denville Scientific. Harvard Apparatus provides instruments for cell and molecular research, physiological instruments, and animal model systems. Molecular Devices specializes in instrumental analysis methods for cell and molecular research. Denville Scientific is a leading supplier of products for cell and molecular biology, including materials for gene and protein expression and cell culture techniques. In the Preclinical Surgical Products segment, Harvard Bioscience operates with the company Hugo Sachs Elektronik. Surgical instruments and complete systems for preclinical research are offered here. These products are popular among scientists worldwide as they have been developed for conducting research with animal models. Analytical Instruments is the segment where the company operates joint ventures to develop instruments for physical, material, and life science research. In this segment, Harvard Bioscience is primarily involved in the joint venture Wasatch Microfluidics, alongside Agilent Technologies, which specializes in the development of instruments for life sciences and biotechnology. As a provider of science and research-related instruments and devices, Harvard Bioscience has a wide range of products to help researchers and scientists enhance their work more effectively. Some of the most popular products from Harvard Bioscience include tissue processing systems, neuroprotection applications, animal model holders, and electrophysiology platforms. Harvard Bioscience also offers a range of products for quality assurance and environmental protection, such as cleanroom and protection devices for material preparation and sterilization. Overall, Harvard Bioscience Inc has an excellent reputation in the industry and is one of the world's leading companies for scientific and research-related products and services. The company constantly strives to improve its products and services and adapts to the needs of its customers. It relies on innovation and continuously works to develop and implement new technologies to meet the demands of the scientific world. Harvard Bioscience ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Harvard Bioscience's Shares Outstanding

Harvard Bioscience's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Harvard Bioscience’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Harvard Bioscience’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Harvard Bioscience’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Harvard Bioscience stock

How many stocks are there of Harvard Bioscience?

The current number of stocks of Harvard Bioscience is 42.42 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Harvard Bioscience are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Harvard Bioscience evolved in recent years?

The number of shares of Harvard Bioscience has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Harvard Bioscience as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Harvard Bioscience?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Harvard Bioscience pay?

Over the past 12 months, Harvard Bioscience paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Harvard Bioscience is expected to pay a dividend of 0 USD.

What is the dividend yield of Harvard Bioscience?

The current dividend yield of Harvard Bioscience is .

When does Harvard Bioscience pay dividends?

Harvard Bioscience pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Harvard Bioscience?

Harvard Bioscience paid dividends every year for the past 0 years.

What is the dividend of Harvard Bioscience?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Harvard Bioscience located?

Harvard Bioscience is assigned to the 'Health' sector.

Wann musste ich die Aktien von Harvard Bioscience kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Harvard Bioscience from 11/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/1/2024.

When did Harvard Bioscience pay the last dividend?

The last dividend was paid out on 11/1/2024.

What was the dividend of Harvard Bioscience in the year 2023?

In the year 2023, Harvard Bioscience distributed 0 USD as dividends.

In which currency does Harvard Bioscience pay out the dividend?

The dividends of Harvard Bioscience are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Harvard Bioscience stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Harvard Bioscience

Our stock analysis for Harvard Bioscience Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Harvard Bioscience Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.